Creso Pharma Limited advised that it has increased its R&D and management capacity following the appointment Dr. Brian Walker as a strategic consultant to the Company and chair to the newly created Scientific Advisory Committee ("Committee"). Dr. Brian Walker is a politician and medical practitioner who has a long-standing commitment to cannabis legalisation and holistic wellness. At the 2021 Western Australian state election, Dr. Walker was elected to the Western Australian Legislative Council as a Legalise Cannabis WA member for the East Metropolitan Region. He is also a board member of not-for-profit group, Mind Medicines Australia, the peak body focused on expanding treatment options available to medical practitioners through the use of psychedelic-assisted treatments. In his role as a strategic consultant, Dr. Walker will oversee and provide input into the Company's medicinal cannabis, hemp and psychedelic products. This includes but is not limited to reviewing and providing input on all the scientific documents related to the research and technical operations of the Company, advising the Board on new scientific developments and commercial opportunities that could support the success of Creso Pharma and evaluating potential R&D and scientific projects for the Company to participate in. As part of his remuneration package, the Company will issue 200,000 options to Brian Walker (or his nominee) per the Appendix 3B released today. As a result of Mr. Walker's position as a board member of Mind Medicine Australia and through the other roles that he has held over his esteemed career, Creso Pharma is also confident that Dr. Walker's appointment will provide the Company with additional access to opportunities, including local and international peak bodies and industry participants. Creso Pharma will leverage his established network to progress a number of near term opportunities. As part of his appointment, Dr. Walker will also act as the chair for the newly established Scientific Advisory Committee. The Committee is expected to significantly expand Creso Pharma's pharmaceutical expertise in all applied science activities. The benefits will extend across all operating divisions of the Company and will substantially increase the scope of work and fast track the current pipeline of product development and R&D initiatives.